Yongmei Ding
About
In The Last Decade
Yongmei Ding
13 papers receiving 427 citations
Peers
Comparison fields: 5 of 65
- Oncology 257
- Molecular Biology 178
- Biomedical Engineering 124
- Immunology 97
- Biomaterials 93
Countries citing papers authored by Yongmei Ding
This map shows the geographic impact of Yongmei Ding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yongmei Ding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yongmei Ding more than expected).
Fields of papers citing papers by Yongmei Ding
This network shows the impact of papers produced by Yongmei Ding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yongmei Ding. The network helps show where Yongmei Ding may publish in the future.
Co-authorship network of co-authors of Yongmei Ding
This figure shows the co-authorship network connecting the top 25 collaborators of Yongmei Ding. A scholar is included among the top collaborators of Yongmei Ding based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yongmei Ding. Yongmei Ding is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 20 | |
| 3 | 116 | |
| 4 | Detecting and phenotyping of aneuploid circulating tumor cells in patients with various malignancies | 2 |
| 5 | 89 | |
| 6 | 34 | |
| 7 | 39 | |
| 8 | 17 | |
| 9 | 3 | |
| 10 | 24 | |
| 11 | 49 | |
| 12 | 42 | |
| 13 | [Drug resistance mechanism of non small cell lung cancer PC9/AB2 cell line with acquired drug resistance to gefitinib]. | 4 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.